Page 465 - An Evidence Review of Active Surveillance in Men With Localized Prostate Cancer

Appendix Table C4.1. Descriptive characteristics of the randomized controlled trials and comparative cohort studies considered
relevant to KQ4 (continued)
Author, Year Study name Comparison Study Sample Inclusion criteria Population description: Quality
[Pubmed ID] /Database duration size (total) Age Comments
PSA (ng/mL)
Study design Tumor grade
Stage
Hadley 207 SEER- RP 1995-2003 14302 used patients with newly diagnosed Age: 60-69 yr, 50.4%; 70-74 yr, B
2010 Medicare vs. in survival prostate cancer, aged <75 yr, 49.6%
20944078 conservative Survival models [a T1/2 tumor stage, receiving RP
management observed sample of or conservative management PSA: NR
Retrospective for up to 17815 within 6 months of diagnosis.
cohort 12 years; patients was Patients were excluded if they Tumor grade: Well-dif., 7.9%;
median used for PS had “unusual histology,” cancer moderately dif., 70.4%; poorly
survival and IV diagnosis was based on death dif., 18.8%; unknown, 11.4%
time from analyses; certificate or autopsy, were not
date of then, from a SEER registry, had Stage: T1, 63.6%; T2, 36.4%
diagnosis exclusion of missing data on the month of
to Dec 31, patients diagnosis or date of death, were
2007 from aged ≤65 yr and had no data
(censoring geographic on the previous year; had
date) was areas with incomplete Medicare Part A and
78 mo fewer than Part B data because of
(IQR=48 50 patients managed care enrollment; had
mo) during the part A enrollment for only 1 year
observation before or after diagnosis; had
period and distant stage disease or not
use of a clinical T1/2 disease; or had
lagged received treatment with
value in the chemotherapy, radiation
IV analysis therapy, or hormone therapy,
resulted in but without surgery.
the
exclusion of
an
additional
3513
patients]

C-150